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METHOTREXATE AS STEROID SPARING AGENT IN 
MYASTHENIA GRAVIS: A RETROSPECTIVE STUDY IN A 
SMALL COHORT OF PATIENTS 
 
INTRODUCTION 
Myasthenia gravis (MG) is an antibody-mediated autoimmune disorder that affects 
neuromuscular junction (NMJ), thus resulting in fluctuating muscle weakness that is 
typically worsen by exertion and improved by rest.1-3 
The incidence of myasthenia gravis ranges from 1.7 to 21 per million persons. 
There is a bimodal distribution with two incidence peaks: in the third decade (strong 
female predominance) and in the elderly (slight male predominance). 4-6 
A recent epidemiological study in more than 2500 MG patients in Australia shows an 
even higher incidence of 24.9 per million person-years.7 
Symptoms may range from ocular muscles weakness to bulbar, respiratory, and limb 
girdle muscles weakness. It is caused by pathogenic autoantibodies directed against the 
acetylcholine receptor (AChR), muscle-specific kinase (MUSK), and lipoprotein related 
protein 4 (LRP4) and these autoantibodies are well established as sensitive and specific 
diagnostic markers.8,9 
Serum AChR positive MG is frequently associated with thymus alterations, that play a 
critical role in the pathogenesis of MG. The most representative thymic alteration is 
thymus follicular hyperplasia (TFH) and is considered the site where the autoimmune 
response to the AChR takes place and is maintained. On the other hand, the defect of T  
 
 
 
cell selection seems to be responsible for the association of MG with thymoma, a tumor 
that can be present in 10–15% of patients.10 
Diagnosis of MG can be confirmed by specific antibody tests and neurophysiological 
tests such as repetitive nerve stimulation (RNS) and single-fiber electromyography 
(SFEMG).  
Treatment of MG is based on different options: 
• improvement of neuromuscular transmission by acetylcholine-esterase inhibitors, e.g. 
pyridostigmine 
• immunosuppression (prednisone, azathioprine, methotrexate, mycofenolate) 
• thymectomy 
•treatment of acute exacerbations (plasmapheresis, intravenous immunoglobulin).9 
 
CLINICAL PRESENTATION 
Extreme fatigability is a major symptom in myasthenia gravis. The combination of 
fatigability with weakness of specific muscles that worsen after exercise gives strong 
clues to diagnosis of MG. 
60% of patients present with ptosis or diplopia, or both, and in 20% of patients, the 
disease is restricted to ocular myastheniagravis.11-13 
Proximal muscular weakness with bulbar muscular weakness are other prominent 
symptoms. Usually proximal muscle weakness is symmetrical.14 
 
 
 
 
 
 
SUBTYPES OF MYASTHENIA GRAVIS IN RELATION TO ANTIBODIES 
PROFILE 
1) MYASTHENIA GRAVIS WITH ACETILCHOLINE RECEPTOR ANTIBODIES 
Serum acetylcholine receptor (AChR) antibodies can be present and detected by 
standard diagnostic testing. AChR autoantibodies are complement-activating and 
antigen-modulating Immunoglobulin G (IgG)1/IgG3 and can modify the NMJ causing a 
severe AChR loss and postsynaptic membrane simplification. 
Patients with AChR antibodies may also present thymic follicular that responds to 
thymectomy. The age of onset of the disease shows a bimodal distribution: early onset 
(first symptom before 50 years old) and late onset (first symptom after 50 years old). 
11,15,16 
Female cases outnumber male cases by three to one.17,18 
This form of MG is associated with HLA-DR3, HLA-B8, and 40,41 all autoimmune 
disorders can be present in relatives of patients affected.19,20 
 
1) MUSK-ASSOCIATED MYASTHENIA GRAVIS 
MUSK is a protein expressed in the postsynaptic muscle membrane that is functionally 
linked to AChR and necessary to maintain AChR function. About 1–4% of patients with 
myasthenia gravis have serum MUSK antibodies. MUSK associated myasthenia gravis 
is rare in children and elder patients.21 
This form of MG is not associated with thymus pathological changes. There is an HLA 
association with HLA-DQ5. 22-24 
 
 
 
 
Patient with MUSK-associated MG have a predominant involvement of cranial and 
bulbar muscles and suffer from dysphagia and dysarthria, they also show an important 
neck muscles weakness, tongue atrophy and respiratory involvement. This form of MG 
is a challenge for neurologist because it does not respond easily to treatment and 
patients need high dose of steroids to control symptoms.25,20 
 
2) LRP4-ASSOCIATED MYASTHENIA GRAVIS 
LRP4 is a receptor for nerve-derived agrin and an activator of MUSK and is necessary 
to maintain AChR function. 2-27% of patients affected by MG can show LRP4 
antibodies, there is a female preponderance.26,27 
The clinical spectrum of LRP4-MG is represented by ocular and generalized mild 
forms. Respiratory insufficiency occurs rarely. Thymic hyperplasia has been reported in 
a small number of patients affected.28 
 
3) TRIPLE ANTIBODY-NEGATIVE GENERALISED MYASTHENIA GRAVIS  
Patients with no detectable AChR, MUSK, or LRP4 antibodies represents an 
heterogenous group, some of these patients show low-affinity antibodies or low 
concentration of antibodies to AChR, MUSK, or LRP4 antigen targets, that are not 
detectable in routine assays. 
          
4) MG ASSOCIATIED TO OTHER ANTIBODIES (very rare forms) 
Recent studies noticed that other antibodies can be involved in MG (agrin, ColQ, 
cortactin, titin and ryanodine receptor). Their role in the disease pathogenesis is not 
completely known that’s why they are not currently used in diagnostic assays.  
 
 
Neuronal agrin is a proteoglycan that binds LRP4 promoting the formation and 
activation of a tetrameric complex that binds and activates MUSK.20,42 
At the NMJ, acetylcholinesterase (AChE) is anchored at the basal lamina by its triple 
collagen tail (ColQ). All ColQ-positive patients are usually women and suffer from 
generalized disease.43 
Cortactin is a tyrosine kinase substrate and acts downstream of agrin/MUSK promoting 
AChR clustering.44  
Antibodies directed against titin and the ryanodine receptor are strongly associated with 
thymoma (titin Abs are positive in 95% and ryanodine receptor Abs in 70% of thymoma 
patients).45,31 
 
        THYMOMA-ASSOCIATED MYASTHENIA GRAVIS 
Thymoma-associated myasthenia gravis is considered as a paraneoplastic disease.  
10-15% of patients with MG also have a thymoma and nearly all of them have 
detectable AChR antibodies with a generalized disease. About 30% of patients with a 
thymoma develop myasthenia gravis.31 
Some data show that hyperplastic changes of myasthenia gravis thymus are related to 
abnormal activation of Toll-like receptors (TLRs), with production of interferons (type 
1) that promote specific anti-AChR autosensitization and abnormal immune system 
activation.32-34 
The occurrence of some viral infections, with a thymic viral replication (especially 
Epstein Barr virus and Parvovirus B19) suggests a link between TLRs signaling and B-
cell activation. 35-37 
 
 
 
T-cell functions are also involved in MG thymus, in fact there is a reduction of 
regulatory T cells in MG thymomas compared with MG hyperplasia and normal 
thymuses and, both patients with thymoma and hyperplastic thymus show a lower 
number of regulatory T cells in peripheral blood.38-40 
 
         OCULAR MYASTHENIA GRAVIS 
Some patients affected by MG have symptoms restricted to the ocular muscles and 
complain of diplopia with ptosis only. About the 90% of this group of patients, who 
complained of ocular symptoms for more than 2 years will remain in this subgroup. 
50% of this group of patients can have detectable AChRantibodies.41 
 
DIAGNOSIS OF MG 
The diagnosis of MG should be suspected in those patients with typical symptoms such 
as diplopia, ptosis, dysphagia, muscle weakness and fatigability that are fluctuating and 
typically worsen by exertion and are improved by rest. 1-3 
All patients with a suspected MG should undergo to specific neurophysiological test 
such as repetitive nerve stimulation (RNS) and single-fiber electromyography 
(SFEMG). SFEMG is considered the most sensitive test when compared to RNS which 
is the most specific.9 
RNS shows the NMJ transmission defect with a decremental response of the compound 
muscle action potential (CMAP) to slow (2–3 Hz) motor repetitive nerve stimulation. 
The decremental response on slow-frequency RNS is due to failure of some muscle 
fibers to reach the threshold and contract. 
 
 
 
The single fiber electromyography in patients affected by MG reveals an elongated 
jitter; the jitter value is the measurement of the variation of the interpotential interval 
between potentials of two motor fibers of the same motor unit. Patients with MG show 
increased jitter values. 46 
Diagnosis should be confirmed even trough specific antibody tests. The anti-AChR 
antibodies are highly specific for MG, in case of negativity we should search for the 
anti-MUSK, LRP4 or others (see above).47 
 
OTHER DIAGNOSTIC TESTS 
1. NEOSTIGMINE TEST 
Neostigmine is a drug that blocks the active site of acetylcholinesterase, this way the 
enzyme cannot break down the acetylcholine molecules before they reach the 
postsynaptic membrane receptors. 
The intramuscular injection of 0.5 mg neostigmine has a great effect on patients with 
MG improving clinical manifestations such as ptosis, dysarthria, limb weakness from 
15 min and the effect persists for about 2 h.9,46,47 
 
2. ICE PACK TEST 
Cold temperature inhibits the enzyme acetylcholinesterase thus leading to a reduced 
breakdown of Ach at ne neuromuscular junction. This test is usually performed on 
patient eyelid by applying a cold ice pack on the ptotic eye for 1 to 2 minutes, an 
improvement of ptosis indicates a positive result.46 
 
 
 
 
3. CT SCAN 
This exam should be performed in all patient with a recent diagnosis of MG, especially 
patients with AChR or LRP4 autoantibodies, in order to detect the presence of a 
thymoma. 
The negativity of the exam does not cause the diagnosis to be discarded.47 
 
TREATMENT OF MYASTHENIA GRAVIS 
 
1. SYMPTOMATIC DRUG TREATMENT 
Acetylcholine esterase inhibitors inhibit the breakdown of ACh at the neuromuscular 
junction increasing the availability of Ach, increasing neuromuscular transmission and 
improving muscle weakness. Among this class of drugs pyridostigmine is the preferred 
one.15 
Pyridostigmine reaches the plasma peak concentrations after 1-2 hours and its effect 
lasts for about 4 hours, this means that it has no long-term side effects. 
Because of its cholinergic stimulation at the autonomic nervous system it can cause 
several side effects that may lead patients to stop treatment; side effects reported include 
nausea, diarrhea, cramps, increased bronchial secretions (not recommended for use in 
patients with asthmatic bronchopathy). There is no optimal dose, it depends on the 
balance between clinical improvement and adverse effects. 
 
 
 
 
 
 
1. IMMUNOSUPPRESSIVE DRUG TREATMENT 
a) Corticosteroids 
Several studies shown that prednisone and prednisolone can improve muscle strength in 
patients with MG. Prednisone is activated by the liver into prednisolone. The effects 
usually manifest after 2–6 weeks. It is recommended to gradually increase the dose of 
corticosteroid in order to avoid initial deterioration.15,48 
Recommended dose is 1.0-1.5 mg/kg per day for both prednisone and prednisolone; 
some authors recommend alternate-day dosing because it can reduce side-effects.12,13 
Corticosteroids should be gradually reduced as soon as possible because of their several 
side effects (diabetes, hypertension, glaucoma, cataract, obesity, osteoporosis).  
It is recommended to add other immunosuppressive agents in patients with MG treated 
with corticosteroids in order to avoid steroid related side effects. 
Some studies suggest that prednisolone alone reduces the risk of developing generalized 
myasthenia gravis in patients with ocular MG. 49-50 
 
b) Azathioprine  
Azathioprine (AZA) is an immunosuppressant, which inhibits DNA and RNA synthesis 
and interferes with T-cell function. The therapeutic response is delayed for 12-18 
months, and maximal effect is obtained after 12–24 months.  
It has several side effects such as flu-like symptoms or gastrointestinal disturbances 
(including pancreatitis that occur within the first few days of treatment). Many patients 
develop hepatitis with asymptomatic elevation of liver enzymes, this leads the clinician 
to withdrawal and often stop the therapy.  
 
 
 
Hematological side effects are represented by leucopenia, anaemia, thrombocytopenia 
or pancytopenia. It is mandatory to monitor full blood cell count and liver enzymes at 
the beginning of therapy.15The recommended dose is 2–3 mg/kg per day. 
AZA is widely used in combination with steroids and as steroid sparing agent, in fact 
some studies showed a better outcome in patients on a combination of AZA and steroids 
than in patients treated with steroids alone.15,51-54 
AZA has been shown to be effective for MG in randomized placebo-controlled studies 
with a significant steroid-sparing activity after 15 months administration although 
several side effects.51(Level A recommendation)  
 
c) Mycophenolate mofetil 
Mycophenolate mofetil (MMF) is an inhibitor of purine nucleotide synthesis and 
interferes exclusively with lymphocyte proliferation. It is not recommended as first line 
therapy for MG even though there are several studies reporting its effectiveness alone or 
in combination with steroids. A retrospective study showed that MMF is effective in 
MG after 6 months, both with prednisone and as monotherapy.55-56 
Other two studies (prospective and controlled trials) do not demonstrate any benefits, 
but these two studies had a short duration (9 months and 12 weeks).56,57 
The recommended dose is 1.5-2 g per day and its therapeutic response is delayed as 
well as AZA (recommendation level B).15 Side-effects are rare and are represented by 
mild headache, hemolytic anemia, nausea and diarrhea. 
 
 
 
 
 
d) Methotrexate 
Methotrexate (MTX) is an inhibitor of dihydrofolate reductase and interferes with DNA 
synthesis. It is widely used in many autoimmune disorders such as rheumatoid arthritis, 
Chron’s disease and myositis.58-60 
There are few studies on the efficacy of MTX in MG and these studies show contrasting 
results. Heckmann et al demonstrated that a dose of MTX of 17 mg weekly is effective 
on steroid-sparing in patients affected by MG and has similar effects and tolerability to 
AZA.61 
Pasnoor performed a 12-month multicenter, randomized, double-blind, placebo-
controlled trial of MTX 20 mg orally every week vs placebo and found no steroid-
sparing benefit of MTX in MG over 12 months of treatment, despite being well-
tolerated. 62 
The recommended dose is 7.5-20 mg per week. MTX has moderate side effect 
(stomatitis, hepatitis, leucopenia). It is recommended to supplement with folic acid. 
Methotrexate should be used in selected patients with MG who do not respond to first 
choice immunosuppressive drugs. 15 
 
e)  Cyclosporin 
Cyclosporin inhibits calcineurin and it is used as immunosuppressive agent in 
autoimmune disorder as well as in patients underwent to organ transplant. 63 
A placebo-controlled double-blind randomized study in 20 patients for 6 months 
showed that cyclosporin improved strength compared with the placebo group.64,65 
 
 
 
 
It has significant side effects such as nephrotoxicity and hypertension and should be 
considered only in patients intolerant or unresponsive to other immunosuppressant 
agents. 66-69 
The recommended dose is 4-6 mg/kg per day (recommendation level B). 
 
f) Cyclophosphamide 
Cyclophosphamide is an alkylating agent and acts as immunosuppressant by reducing 
B-lymphocyte activity and antibody synthesis, at high doses it also affects T-cells.15 
A double-blind, placebo-controlled study on patients with MG demonstrated that 
Cyclophosphamide can improve muscle strength. Intravenous pulses of 
cyclophosphamide promote the reduction of steroids. 70 
It can be assumed orally at the dosage of 3-5 mg/Kg/ per day or through intravenous 
pulses (500 mg/m2every 4 week). 
There is a high risk of toxicity (bone marrow suppression, opportunistic infections, 
bladder toxicity, sterility and neoplasms), this obviously limits its use to those patients 
who do not response to conventional therapy (level B recommendation).15 
 
g) FK506 (tacrolimus) 
Tacrolimus (FK506) inhibits calcineurin and acts as Cyclosporine stopping the 
proliferation of activated T-cells. FK506 has also another effect, it binds ryanodine 
receptor thus facilitating the release of calcium from sarcoplasmic reticulum to 
potentiate excitation–contraction coupling in skeletal muscle.71 
Some case reports and a small open trial all demonstrated a clinical improvement in MG 
with minor side effects.72-76 
 
 
Patients affected by MG with anti-RyR antibodies showed a rapid response to FK506 
treatment indicating asymptomatic effect on muscle strength in addition to the 
immunosuppression.9 
The recommended dose is 3-6 mg per day and this drug should be prescribed in MG 
patients with poorly controlled disease or in patients with RyR antibody-positive MG 
(level C recommendation).15 
 
h) Rituximab  
Rituximab (RTX) is a chimeric IgG1 monoclonal antibody directed against CD20 
antigen, it acts by reducing all type B lymphocytes. RTX has been used in different 
autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus and 
multiple sclerosis. 77-79 
To the date many studies have been performed in order to assess the efficacy of RTX in 
MG and all confirmed its efficacy in improving symptoms, in reducing relapses in 
patients with refractory MG (especially anti MUSK patients) and in its steroids-sparing 
effects. 80-83 
RTX should be considered in patients with moderate and severe myasthenia gravis not 
responding to first-line treatment. Side-effects frequently reported are flu-like 
symptoms, nausea, vomit, hypotension, myelosuppression. A rare side effect is JC-
virus-related progressive multifocal leukoencephalopathy.20 
 
2. THYMECTOMY   
Thymectomy is indicated in all MG patients with evidence of thymoma. A lot of studies 
reported a beneficial effect of thymectomy in myasthenia gravis.11–13,15,84,85 
 
 
It is recommended to perform thymectomy early after symptoms onset. The most used 
methods are video-assisted thoracoscopic and robotic assisted methods.86 Clinical 
improvement after thymectomy occurs gradually after some months and lasts for up to 2 
years. 84  
Thymectomy is an oncological intervention and in some cases chemotherapy or 
radiotherapy are necessary in order to avoid local compression and spread to the 
thoracic cavity. 9 
Thymectomy can be performed even in patients without thymoma, its rationale stands 
on the pathogenic role of the thymus that has been shown in AChR-MG. 10,87,88 
A recent trial compared trans-sternal thymectomy and prednisone with prednisone alone 
in non-thymomatous MG. This trial proved that thymectomy was effective in both 
primary end-points (the time-weighted average quantitative myasthenia gravis score and 
the time-weighted average required dose of prednisone) and in many others secondary 
outcomes (azathioprine usage, hospitalization rate and proportion of patients in minimal 
manifestation status). 89 
 
3. SHORT-TERM IMMUNOMODULATION: PLASMA-EXCHANGE AND 
INTRAVENOUS IMMUNOGLOBULIN 
The main indication for short-term immunomodulation is the treatment of MG 
exacerbations; other secondary indications are the treatment of deterioration after the 
start of steroid therapy, as preparation for thymectomy and as periodic treatment in 
specific cases non-responsive to conventional therapies. 54,55 
The most used methods are plasma-exchange (PLEX) (removes Abs from circulation), 
and intravenous immunoglobulin (IVIg) (interferes with Ab activity). 
 
 
PLEX protocol consists of five exchanges sessions on alternate days and the patients 
need to be hospitalized for all the time; IVIg are usually administered at 2 g/kg over 2–5 
days. 20 
A lot of study were performed in order to assess the efficacy of these two methods in 
patients affected by MG with severe exacerbations and all these studies shown that 
PLEX and IVIg have similar efficacy in clinical improvement, duration of effect and 
tolerance. 90-92 
Usually PLEX is preferred because it has a more rapid effect. There is no difference in 
terms of efficacy of both methods in patients with AChR-MG; patients with MUSK-
MG respond well to PLEX, while the efficacy of IVIg is less consistent in this group of 
patients.93 
IVIg may cause anaphylaxis in IgA-deficient patients and is contraindicated in subjects 
with congestive heart disease and renal insufficiency. The most reported side effects of 
IVIg therapy are nausea, headache and fever. 
PLEX cannot be performed in patients with severe hypotension, sepsis and epilepsy. 
Some adverse events of PLEX are associated with vascular access (infection, 
thrombosis).88  
 
OBJECTIVE OF THE STUDY 
To the date therapy for MG is still debated and controversial: corticosteroids alone or in 
combination with immunosuppressive agents are the most used drugs.47,50 
AZA has been shown to be effective for MG in randomized placebo-controlled studies 
with a significant steroid-sparing activity after 15 months administration although 
several side effects.51 
 
 
But in clinical practice there is a consistent group of patients which cannot assume AZA 
because of hepatological or hematological side effects and a small group of cases, 
especially MUSK positive, unresponsive to AZA. 
We retrospectively evaluated, in our MG cohort of over 850 patients, how many 
patients were treated with MTX in order to determine the efficacy, tolerability, clinical 
improvement and the steroid-sparing effect in our cohort. 
 
PATIENTS AND METHODS 
We found that only 15 patients (8 female and 7 male) above 850 patients, median age is 
about 57 years old were assuming MTX. 
 13 of these patients had an AChR MG and 2 of them had anti-MUSK MG and were 
previously treated with AZA and prednisone with uncomfortable side effects (AZA 
related), and because of this, patients started a combination therapy of MTX (median 
dose 17.5 mg per week) and PDN (median dose at onset 37 mg per day). 
Two out fifteen patients assumed MTX because they also suffer from rheumatoid 
arthritis (RA). 
Patients affected by MUSK-MG assumed a higher dose of PDN.  
Demographic data, as well as pharmacological one’s are shown on Table 1. (Tab.1) 
Mean clinical follow up was about 8 years (from 5 to 10 years).  
Each patient was evaluated 2 times per year using Quantitative Myasthenia Gravis score 
(QMG) and MG-Activity of daily living (MG-ADL). 
QMG score is a test easy to administer and requires minimal equipment, it takes 
approximately 30 minutes to perform. It tests thirteen objective items on a 0 to 3 points 
scale (total score range 0–39), these different items are related to MG symptoms that are  
 
 
double vision, ptosis, facial muscles, swallowing, speech, outstretching of both arms, 
forced vital capacity, hand grip (bilateral), neck muscle strength, outstretching of both 
legs. (Fig 1) 94 
The MG-ADL is a self-administered questionnaire composed of eight items related to 
symptom severity; each response to the item is graded from 0 (normal) to 3 (most 
severe). Two questions are about ocular symptoms, three about oropharyngeal, one 
about respiratory, and two about other functions (Fig. 2). Total MG-ADL scores range 
from 0 to 24. 95 
The scores of MG-ADL and QMG were retrospectively evaluated at the beginning of 
therapy (T0) and after 12 (T12), 24 (T24), 36 (T36) months and at last follow up (Tx). 
Statistical analysis aimed to verify significance of the scores obtained in the five 
different times (T0, T12, T24, T36 and Tx) and was carried out using a non-parametric 
approach, since the study was pointed out on a small sample of patients. 
Parameter modifications during the follow-up were performed using the Freedman and 
post hoc Conover test. 97  
The Mann-Whitney U test was used to compare any statistically significant differences 
in the QMG and MG-ADL parameters. All values of p <0.05 were considered 
significant and the statistical, summary and inferential, post-hoc analysis were 
performed using the R (2) software. 98 
 
RESULTS 
In our group of patients, the median follow-up time was about 8 years. During this 
period all patients underwent to MTX therapy at different dose (median dose 17.5 mg 
per week) and PDN (median dose at onset 37 mg per day) (see Table 1). 
 
 
As shown on fig. 3 QMG score decreases significantly (P <0.001) in the five times. The 
post-hoc analysis allowed to highlight that this decrease is always statistically 
significant except for the T0-T12 period. (fig. 3) 
Even MG-ADL score decreases significantly (P <0.001) in the five times (fig.4). Post-
hoc analysis allowed to test that the decrease is statistically significant in all five follow-
up periods. 
We were able to taper successfully PDN dose starting from 37 mg to a dose of 12.5 mg 
per day; in eleven patients out of fifteen the dose tapering of PDN was = > 20 mg and 
two patients stopped PDN therapy during the period of evaluation. 
 
 
DISCUSSION 
MTX is widely used as an immunosuppressant in many autoimmune diseases such as 
Crohn’s disease and psoriasis and it is first choice drug used as disease modifying agent 
in rheumatoid arthritis (RA). 98 
The first report about MTX and MG is from Mertens et coll, published in 1969. 99 
Nevertheless recent reviews and studies on MG therapies do not include MTX as a 
therapeutic option or refers to MTX as a second/third choice drug in case of failure of 
the other immunosuppressant agents. 100-103  
 As already stated, MTX is a structural analogue of folic acid, it has an anti-proliferative 
effect. Different studies have shown MTX safety and efficacy. A weekly MTX dose of 
17-20 mg produces an optimal efficacy/toxicity ratio in RA patients. 98 
A great advantage of MTX is the weekly dosing, that is usually preferred by non- 
compliant patients.  
 
 
There is a lack in literature about the use of MTX in patients affected with MG. There 
are only two trials about MTX and MG and both studies have shown controversial 
results. Heckmann evaluated the steroid sparing effects of 17.5 mg of MTX weekly 
compared with 2.5 mg/kg AZA and found that the average dose of PDN daily at month 
12 was lower in the MTX-group (0.15 mg/kg prednisone) as compared with that in the 
AZA group in which the PDN dose daily was of 0.31 mg/kg; and the QMG scores 
didn’t differ between two groups. 61 
Conversely Pasnoor and coll. have performed a similar trial about MTX vs placebo in 
AChR MG and in this group of patients the average daily PDN dose decreased in both 
groups with no significative difference, but MTX did not improve secondary measures 
(12-month changes of the Quantitative Myasthenia Gravis Score, the Myasthenia Gravis 
Composite Score, Manual Muscle Testing, the Myasthenia Gravis Quality of Life and 
the Myasthenia Gravis Activities of Daily Living of MG) compared to placebo.62 
Our study is just a retrospective evaluation and is performed in a small cohort of 
patients affected by the most frequent forms of MG, AChR and MUSK MG. 
We found that a long term MTX therapy is well tolerated and safe, in fact no one of the 
patients showed any collateral effects due to MTX therapy. No dose adjustments due to 
side effects were required during all the period of evaluation.  
In this study 15 mg of folate was supplemented every week in order to avoid MTX side 
effects.104-106 
We also found that MTX is an effective therapy in improving clinical manifestation 
evaluated through QMG score and MG-ADL, all 15 patients did not manifest any 
exacerbation of the disease during the period evaluated; and moreover, the median dose  
 
 
 
of PDN decreased critically in our group, at the onset the PDN dose per day was 37 mg 
and at last follow up was 12.5 mg per day. 
As shown on fig.2 MTX begins to be effective after 12 months therapy while AZA that 
is the most used immunosuppressant agent in MG has a delayed therapeutic response as 
demonstrated by two trials studying AZA as steroid-sparing immunosuppressant, in 
these two studies AZA become effective between 15 to 18 months. 52,107-108 
Our small retrospective analysis confirms what’s already known on MTX efficacy, in 
fact  MTX has anti-inflammatory, anti-proliferative and immune-modulatory , its 
immunosuppressive effects includes apoptosis and clonal deletion of activated T cells, 
an inhibitory effect on proliferating cells including B cells, a reduction in pro-
inflammatory cytokine production by T cells and macrophages and CD95-dependant 
apoptosis of activated memory T cells, all these mechanism are involved in the 
pathogenesis of MG. 106 
The MTX recommended dose is 15 mg weekly unless the patient is more than 65 years 
old or his bodyweight is below 50 kg, in these specific cases the recommended dose of 
MTX is 7.5 mg weekly. 106 
A strong major limitation of our study is the small sample size nevertheless, our results 
suggest that MTX has good steroid-sparing efficacy and earlier effects if compared to 
AZA. 
We also demonstrated MTX efficacy even in patients affected with MUSK MG, that 
usually has a poor outcome. 
Further studies are needed in order to confirm our data, we should do future efforts in 
order to find others immunosuppressant agents able to improve MG disease course and  
 
 
 
to reduce the required dose of PDN that is one of the most effective and rapid agents 
used in MG.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tab. 1 
 
 
Legend: * = patient with MUSK-MG; PDN = prednisone; T0 = time of beginning of the 
therapy; TX = time of last follow-up; MTX = methotrexate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SEX AGE 
PDN 
DOSE T0  
PDN 
DOSE 
TX  
MTX 
DOSE 
1 M 72 25 mg 17,5 mg 20 mg 
2 * F 53 60 mg 15 mg 10 mg 
3 * F 72 50 mg 30 mg 20 mg 
4 M 74 25 mg 12,5 mg 20 mg 
5 F 66 25 mg 5 mg 15 mg 
6 M 79 50 mg 10 mg 15 mg 
7 F 35 50 mg 25 mg 15 mg 
8 M 58 25 mg 0 10 mg 
9 F 48 75 mg 10 mg 40 mg 
10 F 63 25 mg 0 7,5 mg 
11 M 49 37,5mg 12,5mg 20 mg 
12 F 41 25 mg 5 mg 15 mg 
13 M 45 25 mg 12,5 mg 15 mg 
14 F 57 37,5 mg 25 mg 15 mg 
15 M 45 25 mg 12,5 mg 20 mg 
 
 
 
Fig. 1 Quantitative Myasthenia Gravis Score 
 
 
             
   
 
 
 
 
 
 
 
 
 
Fig. 2 Myasthenia Gravis Activity of daily living (MG-ADL) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 QMG score decrease  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 MG-ADL decrease  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
1. Spillane J, Higham E and Kullmann DM. Myasthenia gravis. BMJ 2012; 345: e8497. 
 
2. Li Y, Arora Y and Levin K. Myasthenia gravis: newer therapies offer sustained 
improvement. Cleve Clin J Med 2013; 80: 711–721. 
 
3. Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical 
signposts and treatment strategies. Ther Adv Neurol Disord. 2018 Jan 18;11: 
1756285617749134. 
4. Lavrnic D, Basta I, Rakocevic-Stojanovic V, et al. Epidemiological study of adult-
onset myasthenia gravis in the area of Belgrade (Serbia) in the period 1979–2008. 
Neuroepidemiology 2013; 40:190–194. 
5. Montomoli C, Citterio A, Piccolo G, et al. Epidemiology and geographical variation 
of myasthenia gravis in the province of Pavia, Italy. Neuroepidemiology 2012; 38:100–
105.  
6. Carr AS, Cardwell CR, McCarron PO, et al. A systematic review of population 
based epidemiological studies in myasthenia gravis. BMC Neurol 2010; 10:46.  
7. Gattellari M, Goumas C, Worthington JM. A national epidemiological study 
ofmyasthenia gravis in Australia. Eur J Neurol 2012; 19:1413–1420. 
8. Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol. 2014 
Mar;175(3):408-18. 
9. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and 
therapeutic strategies. Lancet Neurol. 2015 Oct;14(10):1023-36. 
 
10. Marx A, Pfister F, Schalke B, et al. The different roles of the thymus in the 
pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev. 2013; 
12:875–884. 
 
11. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and 
biological heterogeneity. Lancet Neurol 2009;8: 475–99. 
 
12. Gilhus NE. Myasthenia and neuromuscular junction. Curr Opin Neurol 2012; 25: 
523–29. 
 
13. Querol L, Illa I. Myasthenia and the neuromuscular junction. Curr Opin Neurol 
2013: 26: 459–65.  
 
 
 
 
 
14. Rodolico C, Toscano A, Autunno M, et al. Limb-girdle myasthenia; clinical, 
electrophysiological and morphological features in familial and autoimmune cases. 
Neuromuscul Disord 2002; 12: 964–69. 
 
15. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune 
neuromuscular transmission disorders. Eur J Neurol 2010; 17: 893–902. 
 
16. Alkhawajah NM, Oger J. Late-onset myasthenia gravis; a reviewwhen incidence in 
older adults keeps increasing. Muscle Nerve 2013;48: 705–10 
 
17. Heldal AT, Owe JF, Gilhus NE, et al. Seropositive myasthenia gravis; a nationwide 
epidemiologic study. Neurology 2009; 73: 150–51. 
 
18. Carr AS, Cardwell CR, McCarron PO, et al. A systematic review ofpopulation based 
epidemiological studies in myasthenia gravis. BMC Neurol 2010; 10: 46 
 
19. Klein R, Marx A, Ströbel P, et al. Autoimmune associations andautoantibody 
screening show focused recognition in patientsubgroups with generalized myasthenia 
gravis. Hum Immunol 2013;74: 1184–93. 
 
20. Evoli A, Iorio R, Bartoccioni E. Overcoming challenges in the diagnosis 
andtreatment of myasthenia gravis. Expert Rev Clin Immunol. 2016;12(2):157-68 
 
21. Skjei KL, Lennon VA, Kuntz NL. Muscle specific kinase autoimmune myasthenia 
gravis in children: a case series. Neuromuscul Disord 2013; 23: 874–82. 
 
22. Bartoccioni E, Scuderi F, Augugiaro A, et al. HLA class II allele analysis in MuSK-
positive myasthenia gravis suggests a role forDQ5. Neurology 2009; 72: 195–97. 
 
23. Klooster R, Plomp JJ, Huijbers MG, et al. Muscle-specific kinase myasthenia gravis 
IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 
2012;135: 1081–101. 
 
24. Alahgholi-Hajibehzad M, Yilmaz V, Guisen-Parman Y, et al. Association of HLA-
DR131*14, -DR131*16 and –DQB1*05 with MuSK-myasthenia gravis in patients from 
Turkey. Hum Immunol2013; 74: 1633–35. 
 
25. Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis; clinical 
findings and response to treatment in two large cohorts. Muscle Nerve 2011; 44: 36–40. 
 
 
 
 
26. Higuchi O, Hamuo J, Motomura M, et al. Autoantibodies to low-density lipoprotein 
receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011; 69: 41822. 
 
27.  Zhang B, Tzartos JS, Viegas S, et al. Autoantibodies to lipoprotein-related protein 4 
in patients with double-negative myasthenia gravis. Arch Neurol 2012; 69: 445–51. 
 
28. Zisimopoulou P, Brenner T, Trakas N, et al. Serological diagnostics in myasthenia 
gravis based on novel assays and recently identified antigens. Autoimmun Rev 2013; 
12: 924–30. 
 
29. Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in” 
seronegative” myasthenia gravis. Brain 2008;131: 1940–52. 
 
30. Cossins J, Belaya K, Zoltowska K, et al. The search for new antigenic targets in 
myasthenia gravis. Ann N Y Acad Sci 2013;1275: 123–28. 
 
31. Skeie GO, Aarli JA, Gilhus NE. Titin and ryanodine receptor antibodies in 
myasthenia gravis. Acta Neurol Scand.006;113(S183):19–23. 
 
32. Cordiglieri C, Marolda R, Franzi S, et al. Innate immunity in myasthenia gravis 
thymus: pathogenic effects of Toll-like receptor 4 signaling on autoimmunity. J 
Autoimmun 2014; 52:74–89. 
 
33. Cufi P, Dragin N, Ruhlmann N, et al. Central role of interferon-beta in thymic 
events leading to myasthenia gravis. J Autoimmun 2014; 52:44–52. 
 
34. Cavalcante P, Barzago C, Baggi F, et al. Toll-like receptors 7 and 9 in myasthenia 
gravis thymus: amplifiers of autoimmunity? Ann N Y Acad Sci2018; 1413:11–24. 
 
35. Cavalcante P, Serafini B, Rosicarelli B, et al. Epstein-Barr virus persistence and 
reactivation in myasthenia gravis thymus. Ann Neurol 2010; 67:726–738. 
 
36. Cavalcante P, Galbardi B, Franzi S, et al. Increased expression of Toll-like receptors 
7 and 9 in myasthenia gravis thymus characterized by active Epstein-Barr virus 
infection. Immunobiology 2016; 221:516–527. 
 
37. Gong L, Li Y, Li X, et al. Detection of human parvovirus B19 infection in the 
thymus of patients with thymic hyperplasia-associated myasthenia gravis. Clin 
Microbiol Infect 2018. 
 
 
 
 
38. Villegas JA, Van Wassenhove J, Le Panse R, et al. An imbalance between 
regulatory T cells and T helper 17 cells in acetylcholine receptor-positive myasthenia 
gravis patients. Ann N Y Acad Sci 2018; 1413:154–162. 
 
39. Kohler S, Keil TOP, Hoffmann S, et al. CD4þ FoxP3þ T regulatory cell subset sin 
myasthenia gravis patients. Clin Immunol 2017; 179:40–46. 
 
40. Mantegazza R, Bernasconi P, Cavalcante P. Myasthenia gravis: from autoantibodies 
to therapy. Curr Opin Neurol. 2018 Oct;31(5):517-525. 
 
41. Haran M, Schattner A, Mate A, et al. Can a rare form of myasthenia gravis shed 
additional light on disease mechanisms? Clin Neurol Neurosurg. 2013; 115:562–566. 
 
42. Burden SJ, Yumoto N, Zhang W. The role of MuSK in synapse formation and 
neuromuscular disease. ColdSpring HarbPerspect Biol. 2013;5: a009167 
 
43. Madhavan R, Gong ZL, Ma JJ, et al. The function of cortactin in the clustering of 
acetylcholine receptors at the vertebrate neuromuscular junction. PLos One. 2009; 4: 
e8478. 
 
44. Gallardo E, Martínez-Hernández E, Titulaer MJ, et al. Cortactin autoantibodies in 
myasthenia gravis. Autoimmun Rev. 2014; 13: 1003–1007. 
 
45. Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis: beyond 
diagnosis? Expert Rev Clin Immunol. 2012; 8:427–438 
 
46. Pasnoor M, Dimachkie MM, Farmakidis C, et al. Diagnosis of Myasthenia Gravis. 
Neurol Clin. 2018 May;36(2):261-274.  
 
47. Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B. Diagnostic and clinical 
classification of autoimmune myasthenia gravis. J Autoimmun. 2014 Feb-Mar;48-
49:143-8.  
 
48. Benatar M, Sanders DB, Wolfe GI, et al. Design of the efficacy of prednisone in the 
treatment of ocular myasthenia (EPITOME) trial. Ann N Y Acad Sci 2012; 1275: 17–
22. 
 
49. Kerty E, Elsais A, Argov Z, et al. EFNS/ENS guidelines for the treatment of ocular 
myasthenia gravis. Eur J Neurol; 2014: 21: 687–93. 
 
50. Benatar M, Kaminski H. Medical and surgical treatment for ocular myasthenia. 
Cochrane Database Syst Rev 2012; CD005081. 
 
51. Schneider-Gold C, Gajdos P, Toyka KV, et al. Corticosteroids for myasthenia 
gravis. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002828.  
 
 
 
52. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of 
prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis 
StudyGroup. Neurology 1998; 50: 1778–1783. 
 
53. Witte AS, Cornblath DR, Parry GJ, et al. Azathioprine in the treatment of 
myasthenia gravis. Ann Neurol 1984; 15: 602–605. 
 
54. Bromberg MB, Wald JJ, Forshew DA, et al. Randomized trial of azathioprine or 
prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci 
1997; 150: 59–62. 
 
55. Hehir MK, Burns TM, Alpers J, et al. Mycophenolate mofetil in AChR-antibody-
positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve. 2010 
May;41(5):593-8.  
 
56. Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial 
of mycophenolate mofetil in myasthenia gravis. Neurology 2008; 71: 400–06. 
 
57. The Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial 
immunotherapy in myasthenia gravis. Neurology 2008; 71: 394–399. 
 
58. Winzer M, Aringer M. Use of methotrexate in patients with systemic lupus 
erythematosus and primary Sjogren’s syndrome. Clin Exp Rheumatol 2010;28: S156–
S159. 
 
59. Aggarwal R, Oddis CV. Therapeutic approaches in myositis. Curr Rheumatol Rep 
2011; 13:182–191. 
 
60. Hashkes PJ, Becker ML, Cabral DA, et al. Methotrexate: new uses for an old drug. J 
Pediatr 2014; 164:231–236. 
 
61. Heckmann JM, Rawoot A, Bateman K, et al. A single-blinded trial of methotrexate 
versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC 
Neurol. 2011 Aug 5; 11:97. 
 
62. Pasnoor M, He J, Herbelin L, et al. Methotrexate in MG Investigators of the Muscle 
Study Group. A randomized controlled trial of methotrexate for patients with 
generalized myasthenia gravis. Neurology. 2016 Jul5;87(1):57-64 
 
63. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 
2000; 47: 119–125. 
 
64. Tindall RS, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, 
randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J 
Med 1987; 316: 719–724. 
 
65. Tindall RS. Immuno-intervention with cyclosporin A in autoimmune neurological 
disorders. J Autoimmun 1992;5(Suppl A): 301–313. 
 
 
 
66.  Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in 
myasthenia gravis. Ann NY Acad Sci 1993; 681: 539–551. 
 
67. Goulon M, Elkharrat D, Lokiec F, et al. Results of a one-year open trial of cyclosporine 
in ten patients with severe myasthenia gravis. Transplant Proc 1988; 20: 211–217.  
 
68. Bonifati DM, Angelini C. Long-term cyclosporine treatment in a group of severe 
myasthenia gravis patients. J Neurol 1997; 244: 542–547. 
 
69. Ciafaloni E, Nikhar NK, Massey JM, et al. Retrospective analysis of the use of 
cyclosporine in myasthenia gravis. Neurology 2000; 55: 448–450. 
 
70. De Feo LG, Schottlender J, Martelli NA, et al. Use of intravenous pulsed 
cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002; 
26:31–36. 
 
71. Timerman AP, Ogunbumni E, Freund E, et al. The calcium release channel of 
sarcoplasmic reticulum is modulated by FK-506-bindingprotein. Dissociation and 
reconstitution of FKBP-12 tothe calcium release channel of skeletal muscle 
sarcoplasmic reticulum. J Biol Chem 1993; 268: 22992–22999. 
 
72. Takamori M, Motomura M, Kawaguchi N, et al. Antiryanodine receptor antibodies and 
FK506 in myasthenia gravis. Neurology 2004; 62: 1894–1896. 
 
73. Konishi T, Yoshiyama Y, Takamori M, et al. Clinical study of FK506 in patients with 
myasthenia gravis. Muscle Nerve 2003; 28: 570–574. 
 
74. Yoshikawa H, Mabuchi K, Yasukawa Y, et al. Low-dose tacrolimus for intractable 
myasthenia gravis. J Clin Neurosci 2002; 9: 627–628. 
 
75. Tada M, Shimohata T, Oyake M, et al. Long-term therapeutic efficacy and safety of 
low-dose tacrolimus (FK506) for myasthenia gravis. J Neurol Sci 2006; 247: 17–20. 
 
76. Nagaishi A, Yukitake M, Kuroda Y. Long-term treatment of steroid-dependent 
myasthenia gravis patients with low-dose tacrolimus. Intern Med 2008; 47: 731–736. 
 
77. Benveniste O, Hilton-Jones D. The role of rituximab in the treatment of myasthenia 
gravis. Eur Neurol Rev 2010; 5: 95–100. 
 
78. Blum S, Gillis D, Brown H, et al. Use and monitoring of low dose rituximab in 
myasthenia gravis. J Neurol Neurosurg Psychiatry 2011;82: 659–63. 
 
79. Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia 
gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011; 
82: 671–73. 
 
 
 
 
80. Diaz-Manera J, Martinez-Hernandez E, Querol L, et al. Long-lasting treatment of 
rituximab in MuSK myasthenia. Neurology 2012; 78: 189–93. 
 
81. Cortés-Vicente E, Rojas-Garcia R, Díaz-Manera J, et al. The impact of rituximab 
infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis. Ann Clin 
Transl Neurol. 2018 Apr 14;5(6):710-716. 
 
82. Nowak RJ, Dicapua DB, Zebardast N, et al. Response of patients with refractory 
myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 2011; 4: 
259–266. 
 
83. Collongues N, Casez O, Lacour A, et al. Rituximab in refractory and non-refractory 
myasthenia: a retrospective multicenter study. Muscle Nerve 2012; 46: 687–691. 
 
84. Gronseth GH, Barohn RJ. Thymectomy for autoimmune myasthenia gravis (an 
evidence-based review). Neurology 2000; 55: 7–15. 
 
85. Cea G, Benatar M, Verdugo RJ, et al. Thymectomy for non-thymomatous myasthenia 
gravis. Cochrane Database Syst Rev 2013; cd008111. 
 
86. Ye B, Tantal J-C, Li W, et al. Video-assisted thoracoscopic surgery versus robotic-
assisted thoracoscopic surgery in the surgical treatment of Masaoka stage I thymoma. 
World J Surg Oncol 2013; 11: 157–62. 
 
87. Mantegazza R, Bonanno S, Camera G, et al. Current and emerging therapies for the 
treatment of myasthenia gravis. Neuropsychiatr Dis Treat. 2011; 7:151–160. 
 
88. Sathasivam S. Current and emerging treatments for the management of myasthenia 
gravis. Ther Clin Risk Manag. 2011; 7:313–323. 
 
89. Wolfe GI, Kaminski HJ, Aban IB et al; MGTX Study Group. Randomized Trial of 
Thymectomy in Myasthenia Gravis. N Engl J Med. 2016 Aug 11;375(6):511-22. doi: 
10.1056/NEJMoa1602489. Erratum in: N Engl J Med. 2017 May 25;376(21):2097. 
 
90. Gajdos P, Chevret S, Clair B, et al Clinical trial of plasma exchange and high-dose 
intravenous immunoglobulins in myasthenia gravis. Ann Neurol. 1997; 41:789–796. 
 
91. Barth D, Nabavi Nouri M, Nwe P, et al. Comparison of IVIg and PLEX in patients with 
myasthenia gravis. Neurology. 2011; 76:2017–2023.  
 
92. Dhawan PS, Goodman BP, Harper CM, et al. IVIG versus PLEX in the treatment of 
worsening myasthenia gravis: what is the evidence? A critically appraised topic. 
Neurologist. 2015; 19:145–148. 
 
93. Evoli A, Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to 
muscle-specific kinase. Autoimmun Rev. 2013; 12:931–935. 
 
 
 
 
94. Barohn RJ, McIntire D, Herbelin L, et al. Reliability testing of the quantitative 
myasthenia gravis score. Ann N Y Acad Sci. 1998 May 13; 841:769-72 
 
95. Wolfe GI, Herbelin L, Nations SP, et al. Myasthenia gravis activities of daily living 
profile. Neurology. 1999 Apr 22;52(7):1487-9. 
 
96. W. J. Conover (1999). Practical Nonparametric Statistics. Third Edition, Wiley & Sons. 
 
97. The R Project for Statistical Computing (www.r-project.org/). 
 
98. Visser K, van der Heijde D: Optimal dosage and route of administration of methotrexate 
in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009, 
68:1094-99. 
 
99. Mertens HG, Balzereit F, Leipert M. The treatment of severe myasthenia gravis with 
immunosuppressive agents. Eur Neurol. 1969;2(6):321-39. 
 
100. Richman DP, Agius MA: Treatment of autoimmune myasthenia gravis. Neurology 
2003, 61:1652-61. 
 
101. Pruitt JN, Swift TR: Therapies for disorders of the neuromuscular junction. Arch 
Neurol 2002, 59:739-42. 
 
102. Keesey JC: Clinical evaluation and management of myasthenia gravis. Muscle Nerve 
2004, 29:484-505. 
 
103. Hilton-Jones D: When the patient fails to respond to treatment: myasthenia gravis. 
Pract Neurol 2007, 7:405-11 
 
104. van Ede AE, Laan RF, Rood MJ, et al: Effect of folic or folinic acid supplementation 
on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, 
multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001, 
44:1515-24. 
 
105. Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate 
associated safety and efficacy in inflammatory disease: a systematic review. Br J 
Dermatol 2009, 160:622-8. 
 
106. Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties of 
methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 
1998, 102:322-8. 
 
107. Hart IK, Sathasivam S, Sharshar T: Immunosuppressive agents for myasthenia gravis. 
Cochrane Database Syst Rev 2007, CD005224. 
 
108. Keesey JC: Clinical evaluation and management of myasthenia gravis. Muscle Nerve 
2004, 29:484-505. 
 
 
